ARTICLE | Deals
TeneoBio shareholders gain another exit as AstraZeneca buys spinout
Pharma adds bispecific with purchase of TeneoTwo, bringing more returns to shareholders, including Lightspeed and Sutter Hill
July 5, 2022 8:00 PM UTC
Former shareholders of TeneoBio gained another windfall Tuesday when AstraZeneca said it would acquire single-asset spinout TeneoTwo for $100 million up front, adding a clinical bispecific T cell engager to its pipeline.
The deal brings the total sale price of TeneoBio Inc. and associated assets to $1.4 billion thus far, across three upfront payments. ...